CTLA4 and metastatic melanoma: Upon further review of the patient’s medical history and prior treatment regimen, it was discovered that he had been receiving immune checkpoint inhibitor (ICI) therapy, specifically nivolumab (a PD-1 inhibitor) and ipilimumab (a CTLA-4 inhibitor), for his metastatic melanoma.